SEC Form 4 research

Terns Pharmaceuticals, Inc. insider transactions

Inspect Terns Pharmaceuticals, Inc.'s public SEC insider acquisitions and sales, reporting owners and source receipts.

As of 2026-10-07T00:29:11.873Z

Issuer CIK
0001831363
Reporting owners
39
Officers and directors
13

Recent insider disclosures

This table includes purchases, sales and awards in the public filing record. Awards and open-market purchases are distinct transaction codes. For historical research, use the public availability date to determine when the transaction was knowable.

Read code P as a purchase, S as a sale and A as an award. An award is an acquisition, but it is not an open-market purchase. Open the filing receipt to check the transaction details.

No records are available for this view.

Most recent 90-day source activity, up to 50 rows. No rows means no matching recent records, not no historical activity.

Officers and directors in the directory

Yoon Seokho Bryan00017611645
Sundaram Senthil Vel00017623165
Gengos Andrew000156362321
Burroughs Amy L.000187256412
Vignola Mark J.00017754298
Quigley Jill M.000179978011
OrbiMed Genesis GP LLC0001808744216
OrbiMed Asia GP III, L.P.000184146212
Lu Hongbo000176758418
GORDON CARL L0001282930150
Jung Melita Sun00019624071
Kuriakose Emil00018924137
OrbiMed Advisors III Ltd000184153712
ORBIMED ADVISORS LLC00010559511,014
OrbiMed Capital GP VII LLC0001760648191

Which transactions qualify for the company tracker

The company strategy uses verified officers and directors with qualifying acquisitions at this issuer. Other reporting owners may appear in source records without becoming strategy signals.

Strategy eligibility is held while filing coverage is unresolved.

Historical follower simulations are separate from these source transactions. They do not establish live trading results.